




1 **Extended Data Fig. 1 Age-associated bone phenotypes in OPG KO mice**


- 2 **a**, μ CT analysis of trabecular bone parameters in femora from young and middle-aged WT and
- 3 OPG KO mice. $n = 5$ biological replicates. Scale bar, 1 mm.
- 4 **b–d**, Immunofluorescence of Perilipin⁺ (**b**), Ki67⁺ (**c**), and CD41a⁺ (**d**) cells in bone marrow

from young and middle-aged WT and OPG KO mice. $n = 5$ biological replicates. Scale bar, 50 μm .

e, Quantitative RT–PCR analysis of *p16* and *p21* expression in young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates.

f–h, Immunofluorescence of Ki67⁺ (**f**), CD41a⁺ (**g**), and Perilipin⁺ (**h**) cells in femora from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 50 μm .

a–h, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired two-tailed Welch’s *t*-test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, ns, not significant).



Extended Data Fig. 2 RANK⁺ endothelial cells are increased in middle-aged bone

marrow

a, Immunofluorescence of femora from middle-aged RANK-tom mice stained for CD31 and

Emcn, F4/80, and LepR. $n = 5$ biological replicates. Scale bar, 50 μm .

b, RANKL immunofluorescence in femora from young and middle-aged WT mice. $n = 5$

biological replicates. Scale bar, 50 μm .


a, Data are presented as median with interquartile range. Statistical significance was determined

using the Kruskal–Wallis test followed by Dunn’s multiple-comparisons test (* $P < 0.05$, ** $P <$

0.01).

b, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired two-

tailed Welch’s t -test (* $P < 0.05$).



28 Extended Data Fig. 3 Depletion of endothelial Rank improves aging-associated

29 decline in bone formation

30 **a**, Immunofluorescence of CD31 and Emcn in femora from middle-aged control and EC-RANK
 31 cKO mice after intravenous injection of Fluor555-rRANKL. $n = 3$ biological replicates. Scale
 32 bar, 50 μ m.

33 **b**, Toluidine blue staining of tibial sections from middle-aged control and EC-RANK cKO
 34 mice. $n = 7$ biological replicates. Scale bar, 50 μ m.

35 **c**, Osterix immunofluorescence in femora from middle-aged control and EC-RANK cKO mice.
 36 $n = 4$ biological replicates. Scale bar, 50 μ m.

37 **d**, Calcein double labeling of tibiae to determine bone formation rate. $n = 7$ biological
 38 replicates. Scale bar, 50 μ m.


39 **e**, TRAP staining of tibiae from middle-aged control and EC-RANK cKO mice. $n = 7$ biological

40 replicates. Scale bar, 50 μm .

41 **b–e**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired

42 two-tailed Welch's *t*-test (* $P < 0.05$, ** $P < 0.01$, ns, not significant).

43



44 **Extended Data Fig. 4** **Deletion of endothelial Rank restores aging-associated**

45 **senescent cell accumulation and aberrant HSC output**

46 **a**, Flow cytometry analysis of SPiDER-β-gal⁺ cells in bone marrow from young and middle-

47 aged control and EC-RANK cKO mice. *n* = 3 biological replicates.

48 **b**, SPiDER-β-gal staining in femora from young and middle-aged control and EC-RANK cKO


49 mice. *n* = 6 biological replicates. Scale bar, 50 μm.

50 **c**, Ki67 immunofluorescence in femora from middle-aged control and EC-RANK cKO mice. *n*

51 = 6 biological replicates. Scale bar, 50 μm.

52 **d**, Hematoxylin and eosin-stained tibial sections from middle-aged control and EC-RANK cKO
53 mice. *n* = 7 biological replicates. Scale bar, 50 μ m.
54 **e**, Quantitative RT-PCR analysis of SASP gene expression in tibiae from middle-aged control
55 and EC-RANK cKO mice. *n* = 5 biological replicates.
56 **f**, Quantification of bone marrow cellularity in femora from young and middle-aged control and
57 middle-aged EC-RANK cKO mice before and 1 or 2 weeks after intravenous administration of
58 5-FU (250 mg/kg). *n* = 6 biological replicates.
59 **a–e**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–
60 Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired
61 two-tailed Welch’s *t*-test (**P* < 0.05, ***P* < 0.01, ****P* < 0.001, ns, not significant).

62



63 Extended Data Fig. 5 Characterization of endothelial cells by scRNA-seq and FACS

64 analysis, and effects of RANKL on IL-1 β and SASP expression

65 **a**, UMAP visualization of reanalyzed scRNA-seq data (GSE145477) from bone marrow of 16-

66 month-old mice. Feature plots show expression of canonical marker genes in BMSCs,

67 osteoblasts, immune cells, and endothelial cells.

68 **b,c**, Cell sorting of endothelial cells (CD31⁺CD45⁻Ter119⁻) and stromal cell-rich fractions

69 (CD31⁻CD45⁻Ter119⁻), and quantitative RT-PCR analysis of *Cdh5* and *Lepr* expression. $n = 3$

70 biological replicates.

71 **d**, CD31 and Emcn immunofluorescence and SPiDER- β -gal staining in femora. $n = 6$ biological

72 replicates. Scale bar, 50 μ m.

73 **e**, Quantitative RT-PCR analysis of SASP gene expression in HUVECs transfected with

74 *Tnfrsf11a* or control vector and treated with RANKL (100 ng/mL) for 24 h. $n = 5$ biological

75 replicates.


76 **f**, Quantitative RT-PCR analysis of SASP gene expression in bone marrow macrophages

77 treated with RANKL (100 ng/mL) for 24 h or untreated. $n = 3$ biological replicates.

78 **b–f**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired

79 two-tailed Welch's *t*-test (* $P < 0.05$, ** $P < 0.01$).

80



81 **Extended Data Fig. 6 Identification of *Il1r1*-expressing clusters and effects of IL-1β**

82 **on senescence**

83 **a**, UMAP visualization of scRNA-seq data from bone marrow of 1.5-month-old and 16-month-

84 old mice.

85 **b**, Feature plots showing expression of canonical marker genes.

86 c, Volcano plot showing DEGs between *Il1r1*⁺ and *Il1r1*⁻ BMSCs.

87 d, Alkaline phosphatase staining and quantification of alkaline phosphatase (ALP) activity. n =

88 3 biological replicates.

89 e, Violin plots showing ROS-related pathway activity and representative oxidative stress

90 response genes in *Il1r1*⁻ and *Il1r1*⁺ BMSCs. The left panel shows the UCell score for the GO

91 cellular response to oxidative stress pathway, and the right panels show expression levels of

92 *Nfe2l2* and *Txnrd1*. Each dot represents one cell. White horizontal bars indicate the median.

93 f, Representative images of DCFH-DA staining in ST2 cells treated with IL-1 β with or without

94 N-acetylcysteine (NAC) for 10 min. Quantification of intracellular ROS levels by integrated

95 density (IntDen) is shown. n = 5 biological replicates. Scale bar, 50 μ m.

96 g, Representative images of JC-1 staining in ST2 cells treated with IL-1 β . Quantification of the

97 JC-1 red/green fluorescence intensity ratio by ROI analysis of individual cells is shown. Red

98 and green fluorescence indicate high and low mitochondrial membrane potential ($\Delta\Psi$ m). Values

99 represent the mean of all analyzed cells. n = 3 biological replicates. Scale bar, 50 μ m.

100 h, Quantitative RT-PCR analysis of *Ifnb* expression in ST2 cells treated with or without IL-1 β .

101 n = 3 biological replicates.

102 i, Representative western blots of p16 and p21 in ST2 cells treated with IL-1 β for 10 days.

103 Quantification of p16 and p21 protein expression normalized to β -actin is shown. n = 3

104 biological replicates.

105 d-i, Data are presented as mean $\pm$ s.d. Statistical significance was determined by one-way
106 ANOVA followed by Dunnett's multiple-comparisons test (d, f), Wilcoxon rank-sum test (e),
107 unpaired two-tailed Welch's t-test (g-i). (* $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$).